HIV inhibiting pyrimidines derivatives

Details for Australian Patent Application No. 2002329238 (hide)

Owner Janssen Pharmaceutica N.V.

Inventors Guillemont, Jerome Emile Georges; Lewi, Paulus, Joannes; De Jonge, Marc Rene; Heeres, Jan; Palandjian, Patrice; Koymans, Lucien Maria Henricus; Daeyaert, Frederik Frans Desire; Vinkers, Hendrik Maarten; Janssen, Paul Adriaan Jan; Van Aken, Loen Jeanne Alfons

Agent Shelston IP

Pub. Number AU-B-2002329238

PCT Number PCT/EP02/08953

PCT Pub. Number WO2003/016306

Priority 02077748.8 10.06.02 EP; 01203090.4 13.08.01 EP

Filing date 9 August 2002

Wipo publication date 3 March 2003

Acceptance publication date 24 January 2008

International Classifications

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/5355 (2006.01) - Non-condensed oxazines containing further heterocyclic rings

A61K 31/541 (2006.01) - Non-condensed thiazines containing further heterocyclic rings

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 31/18 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

C07C 211/00 (2006.01) Compounds containing amino groups bound to a carbon skeleton

C07C 255/42 (2006.01) Carboxylic acid nitriles

C07C 257/12 (2006.01) Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines

C07D 233/96 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 239/46 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/47 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 239/48 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 407/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group

C07D 409/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

30 January 2003 Complete Application Filed

  Priority application(s): 02077748.8 10.06.02 EP; 01203090.4 13.08.01 EP

29 May 2003 Application Open to Public Inspection

  Published as AU-B-2002329238

24 January 2008 Application Accepted

  Published as AU-B-2002329238

17 April 2008 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 27 Mar 2008. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

22 May 2008 Standard Patent Sealed

28 August 2008 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 27 Mar 2008

12 July 2012 Extension of Term of Standard Patents

  Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 23 Dec 2011 For the goods EDURANT rilpivirine Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002329239-DISPLACEMENT PUMP

2002329237-Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as NMDA antagonists